CSOWM ACTUAL 2026 QUESTIONS AND
VERIFIED ANSWERS
Save
Practice questions for this set
Learn 1 /7 Study with Learn
light: 1.1-2.9
moderate: 3-5.9
vigorous: >6
Choose an answer
1 MET levels 2 Management of BMI >/= 25
3 Hormonal signals for appetite 4 Management of BMI >/=40
Don't know?
Terms in this set (133)
Management of BMI >/= 25 Diet, Exercise, Behavior
,Management of BMI >/=30 Diet, exercise, behavior + pharmacotherapy
Management of BMI >/= 27 + Diet, exercise, behavior + pharmacotherapy
comorbidity
Management of BMI >/=35 + Bariatric surgery
cormorbidity
Management of BMI >/=40 Bariatric surgery
Co-morbidities T2DM
HTN
OSA and other respiratory disorders
NAFLD
OA
lipid abnormalities
gastrointestinal disorders
heart disease
Medication assessment Every month x3 months, then every 3 months
Effective weight loss % >/=5% in 3 months
Avoid these wt loss meds with Sympathomimetics
HTN/HD (phentermine/diethylproprion)
Avoid these wt loss medications Sypathomimetics
with CVD
T2DM treatment + medications to GLP-1 analog (mitigates associated weight gain
support weight loss due to insulin) or SGLT-2 inhibitors + metformin. If
using insulin, recommend basal instead of combo
, Drugs that induce weight gain Tricyclic antidepressants (Amitriptyline)
oral contraceptives (Ortho Tri-Cyclen, Yaz)
antipsychotics (Risperidone)
anticonvulsants
glucocorticoids (cortisol)
sulfonyureas- ( Glimepiride, Glipizide)
glitazones (Actos)
B-blockers (Propranolol, Metoprolol, Atenolol)
Hormonal signals for appetite CCK- duodenum
K cells- duodenum and jejunum: gatric inhibitory
polypeptide
PYY- ileum and colon
GLP-1 -ileum
Pancreas- Insulin
Adipose tissue: Leptin
Liver- glucagon
GLP-1 Secreted in response to glucose and promotes
insulin release from pancreas and satiety
Ghrelin produced in the stomach, orexigenic
Leptin proportional to fat mass, anorexigenic
Inhibits appetite
PYY Ileum and colon, anorexigenic
CCK duodenum, anorexigenic
VERIFIED ANSWERS
Save
Practice questions for this set
Learn 1 /7 Study with Learn
light: 1.1-2.9
moderate: 3-5.9
vigorous: >6
Choose an answer
1 MET levels 2 Management of BMI >/= 25
3 Hormonal signals for appetite 4 Management of BMI >/=40
Don't know?
Terms in this set (133)
Management of BMI >/= 25 Diet, Exercise, Behavior
,Management of BMI >/=30 Diet, exercise, behavior + pharmacotherapy
Management of BMI >/= 27 + Diet, exercise, behavior + pharmacotherapy
comorbidity
Management of BMI >/=35 + Bariatric surgery
cormorbidity
Management of BMI >/=40 Bariatric surgery
Co-morbidities T2DM
HTN
OSA and other respiratory disorders
NAFLD
OA
lipid abnormalities
gastrointestinal disorders
heart disease
Medication assessment Every month x3 months, then every 3 months
Effective weight loss % >/=5% in 3 months
Avoid these wt loss meds with Sympathomimetics
HTN/HD (phentermine/diethylproprion)
Avoid these wt loss medications Sypathomimetics
with CVD
T2DM treatment + medications to GLP-1 analog (mitigates associated weight gain
support weight loss due to insulin) or SGLT-2 inhibitors + metformin. If
using insulin, recommend basal instead of combo
, Drugs that induce weight gain Tricyclic antidepressants (Amitriptyline)
oral contraceptives (Ortho Tri-Cyclen, Yaz)
antipsychotics (Risperidone)
anticonvulsants
glucocorticoids (cortisol)
sulfonyureas- ( Glimepiride, Glipizide)
glitazones (Actos)
B-blockers (Propranolol, Metoprolol, Atenolol)
Hormonal signals for appetite CCK- duodenum
K cells- duodenum and jejunum: gatric inhibitory
polypeptide
PYY- ileum and colon
GLP-1 -ileum
Pancreas- Insulin
Adipose tissue: Leptin
Liver- glucagon
GLP-1 Secreted in response to glucose and promotes
insulin release from pancreas and satiety
Ghrelin produced in the stomach, orexigenic
Leptin proportional to fat mass, anorexigenic
Inhibits appetite
PYY Ileum and colon, anorexigenic
CCK duodenum, anorexigenic
